News articles about Aimmune Therapeutics (NASDAQ:AIMT) have trended somewhat positive on Sunday, according to Accern Sentiment. The research group scores the sentiment of media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Aimmune Therapeutics earned a news impact score of 0.17 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 45.4983873811199 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

These are some of the news articles that may have impacted Accern Sentiment’s rankings:

Several analysts have commented on the stock. Credit Suisse Group increased their price target on shares of Aimmune Therapeutics from $36.00 to $45.00 and gave the company an “outperform” rating in a research report on Monday, October 23rd. Wedbush reissued an “outperform” rating and set a $70.00 price target (up from $42.00) on shares of Aimmune Therapeutics in a research report on Monday, October 23rd. Piper Jaffray Companies set a $38.00 price target on shares of Aimmune Therapeutics and gave the company a “buy” rating in a research report on Saturday, October 21st. Zacks Investment Research raised shares of Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, October 16th. Finally, BidaskClub lowered shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. Aimmune Therapeutics currently has an average rating of “Hold” and an average price target of $51.00.

Aimmune Therapeutics (NASDAQ:AIMT) opened at $30.31 on Friday. Aimmune Therapeutics has a 1 year low of $15.97 and a 1 year high of $37.50.

Aimmune Therapeutics (NASDAQ:AIMT) last announced its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.65) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by ($0.01). equities research analysts forecast that Aimmune Therapeutics will post -2.57 earnings per share for the current fiscal year.

In related news, insider Susan E. Barrowcliffe sold 18,390 shares of the stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $22.00, for a total value of $404,580.00. Following the completion of the transaction, the insider now directly owns 3,223 shares of the company’s stock, valued at approximately $70,906. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Stephen George Dilly sold 100,000 shares of the stock in a transaction that occurred on Monday, September 25th. The stock was sold at an average price of $25.01, for a total transaction of $2,501,000.00. The disclosure for this sale can be found here. Insiders sold a total of 315,815 shares of company stock valued at $8,337,379 over the last ninety days. 24.56% of the stock is currently owned by insiders.

WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Aimmune Therapeutics (AIMT) Share Price” was first reported by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at https://www.watchlistnews.com/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-aimmune-therapeutics-aimt-share-price/1680524.html.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Insider Buying and Selling by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.